Mentor Corp. has begun clinical testing of another botulinum product stemming from a licensing agreement with the Wisconsin Alumni Research Foundation.
The Phase 1 safety and dose escalation study involves a botulinum toxin type A product focused on treating the pain associated with adult onset spasmodic torticollis/cervical dystonia.